^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

UBE3A deletion

i
Other names: UBE3A, Ubiquitin Protein Ligase E3A, EPVE6AP, HPVE6A, E6-AP, ANCR, AS, Human Papilloma Virus E6-Associated Protein, Human Papillomavirus E6-Associated Protein, Oncogenic Protein-Associated Protein E6-AP, HECT-Type Ubiquitin Transferase E3A, Renal Carcinoma Antigen NY-REN-54, E6AP Ubiquitin-Protein Ligase, Ubiquitin-Protein Ligase E3A, FLJ26981, CTCL Tumor Antigen Se37-2, Angelman Syndrome, E6AP
Entrez ID:
1m
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome (clinicaltrials.gov)
P1/2, N=51, Active, not recruiting, Ionis Pharmaceuticals, Inc. | Trial completion date: Jan 2025 --> Mar 2029 | Trial primary completion date: Jan 2025 --> Mar 2029
Trial completion date • Trial primary completion date
|
UBE3A (Ubiquitin Protein Ligase E3A)
|
UBE3A deletion
5ms
Enrollment closed
|
UBE3A (Ubiquitin Protein Ligase E3A)
|
UBE3A deletion